Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 98-106

  Meyr, Franziska ^a   Escherich, Gabriele ^b   Mann, Georg ^c   Klingebiel, Thomas ^d   Kulozik, Andreas ^e   Rossig, Claudia ^f   Schrappe, Martin ^g   Henze, Günter ^a   von Stackelberg, Arend ^a   Hitzler, Johann ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acute lymphoblastic leukaemia; Down syndrome; Outcomes; Relapse; Treatment

Indexed keywords

IDARUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; DRUG EFFECT; EVENT FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; MALE; OVERALL SURVIVAL; PHYSICAL TOLERANCE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84879075968     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12348     Document Type: Article

References (34)

1. Arenson, E.B. Jr & Forde, M.D. (1989) Bone marrow transplantation for acute leukemia and Down syndrome: report of a successful case and results of a national survey. Journal of Pediatrics, 114, 69-72.
2. Barredo, J.C., Devidas, M., Lauer, S.J., Billett, A., Marymont, M., Pullen, J., Camitta, B., Winick, N., Carroll, W. & Ritchey, A.K. (2006) Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. Journal of Clinical Oncology, 24, 3142-3149.
3. Bassal, M., La, M.K., Whitlock, J.A., Sather, H.N., Heerema, N.A., Gaynon, P.S. & Stork, L.C. (2005) Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatric Blood & Cancer, 44, 21-28.
4. Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. & van't Veer, M.B. (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 9, 1783-1786.
5. Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., Cario, G., Schrappe, M., Stanulla, M., Strehl, S., Haas, O.A., Mann, G., Binder, V., Borkhardt, A., Kempski, H., Trka, J., Bielorei, B., Avigad, S., Stark, B., Smith, O., Dastugue, N., Bourquin, J.P., Tal, N.B., Green, A.R. & Izraeli, S. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, 372, 1484-1492.
6. Borgmann, A., von Stackelberg, A., Hartmann, R., Ebell, W., Klingebiel, T., Peters, C. & Henze, G. (2003) Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood, 101, 3835-3839.
7. Borgmann, A., Zinn, C., Hartmann, R., Herold, R., Kaatsch, P., Escherich, G., Moricke, A., Henze, G. & von Stackelberg, A. (2008) Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. European Journal of Cancer, 44, 257-268.
8. Buhrer, C., Hartmann, R., Fengler, R., Dopfer, R., Gadner, H., Gerein, V., Gobel, U., Reiter, A., Ritter, J. & Henze, G. (1993) Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Medical and pediatric oncology, 21, 470-476.
9. Buitenkamp, T.D., Mathôt, R.A.A., de Haas, V., Pieters, R. & Zwaan, C.M. (2010) Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica, 95, 1106-1113.
10. Buitenkamp, T., Izraeli, S., Zimmermann, M., Forestier, E., Heerema, N.A., van den Heuvel, M.M., Pieters, R., de Haas, V., Silverman, L.B., Schmiegelow, K., Liang, D.-C., Horibe, K., Arico, M., Cazzaniga, G., Basso, G., Rabin, K.R., Schrappe, M., Cario, G., Mann, G., Mondelaers, V., Lammens, T., Cave, H., Stark, B., Moorman, A.V., Vora, A.J., Hunger, S., Pui, C.-H., Mullighan, C.G., Manabe, A., Escherich, G., Kowalczyk, J., Whitlock, J.A. & Zwaan, C.M. (2011) Acute lymphoblastic leukemia in children with down syndrome: a report from the Ponte Di Legno study group. Blood (ASH Annual Meeting Abstracts), 118, 3579.
11. Dordelmann, M., Schrappe, M., Reiter, A., Zimmermann, M., Graf, N., Schott, G., Lampert, F., Harbott, J., Niemeyer, C., Ritter, J., Dorffel, W., Nessler, G., Kuhl, J. & Riehm, H. (1998) Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia, 12, 645-651.
12. Eapen, M., Raetz, E., Zhang, M.J., Muehlenbein, C., Devidas, M., Abshire, T., Billett, A., Homans, A., Camitta, B., Carroll, W.L. & Davies, S.M. (2006) Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood, 107, 4961-4967.
13. Einsiedel, H.G., von Stackelberg, A., Hartmann, R., Fengler, R., Schrappe, M., Janka-Schaub, G., Mann, G., Hahlen, K., Gobel, U., Klingebiel, T., Ludwig, W.-D. & Henze, G. (2005) Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. Journal of Clinical Oncology, 23, 7942-7950.
14. Fine, J.P. & Gray, R.J. (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of American Statistical Association, 94, 496-509.
15. Gaikwad, A., Rye, C.L., Devidas, M., Heerema, N.A., Carroll, A.J., Izraeli, S., Plon, S.E., Basso, G., Pession, A. & Rabin, K.R. (2009) Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. British Journal of Haematology, 144, 930-932.
16. Garre, M.L., Relling, M.V., Kalwinsky, D., Dodge, R., Crom, W.R., Abromowitch, M., Pui, C.H. & Evans, W.E. (1987) Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. Journal of Pediatrics, 111, 606-612.
17. Gaynon, P.S., Qu, R.P., Chappell, R.J., Willoughby, M.L., Tubergen, D.G., Steinherz, P.G. & Trigg, M.E. (1998) Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse-the Children's Cancer Group Experience. Cancer, 82, 1387-1395.
18. Goto, H., Inukai, T., Inoue, H., Ogawa, C., Fukushima, T., Yabe, M., Kikuchi, A., Koike, K., Fukushima, K., Isoyama, K., Saito, T., Ohara, A., Hanada, R., Iwamoto, J., Hotta, N., Nagatoshi, Y., Okamura, J. & Tsuchida, M. (2011) Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group. International Journal of Hematology, 93, 192-198.
19. Hagedorn, N., Acquaviva, C., Fronkova, E., von Stackelberg, A., Barth, A., zur Stadt, U., Schrauder, A., Trka, J., Gaspar, N., Seeger, K., Henze, G., Cave, H. & Eckert, C. (2007) Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood, 110, 4022-4029.
20. Harvey, R.C., Mullighan, C.G., Chen, I.M., Wharton, W., Mikhail, F.M., Carroll, A.J., Kang, H., Liu, W., Dobbin, K.K., Smith, M.A., Carroll, W.L., Devidas, M., Bowman, W.P., Camitta, B.M., Reaman, G.H., Hunger, S.P., Downing, J.R. & Willman, C.L. (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood, 115, 5312-5321.
21. Hasle, H., Clemmensen, I.H. & Mikkelsen, M. (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, 355, 165-169.
22. Henze, G., Fengler, R., Hartmann, R., Kornhuber, B., Janka-Schaub, G., Niethammer, D. & Riehm, H. (1991) Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood, 78, 1166-1172.
23. Hertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz, M., Chalker, J., Shiloh, R., Iacobucci, I., Shochat, C., Zeligson, S., Cario, G., Stanulla, M., Strehl, S., Russell, L.J., Harrison, C.J., Bornhauser, B., Yoda, A., Rechavi, G., Bercovich, D., Borkhardt, A., Kempski, H., te Kronnie, G., Bourquin, J.P., Domany, E. & Izraeli, S. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115, 1006-1017.
24. Kearney, L., Gonzalez De Castro, D., Yeung, J., Procter, J., Horsley, S.W., Eguchi-Ishimae, M., Bateman, C.M., Anderson, K., Chaplin, T., Young, B.D., Harrison, C.J., Kempski, H., So, C.W.E., Ford, A.M. & Greaves, M. (2009) Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood, 113, 646-648.
25. Klein, J. & Moeschberger, M. (2003) Survival Analysis: Techniques of Censored and Truncated Data, 2nd edn. Springer Verlag, New York, NY.
26. Ko, R.H., Ji, L., Barnette, P., Bostrom, B., Hutchinson, R., Raetz, E., Seibel, N.L., Twist, C.J., Eckroth, E., Sposto, R., Gaynon, P.S. & Loh, M.L. (2010) Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium Study. Journal of Clinical Oncology, 28, 648-654.
27. Maloney, K.W. (2011) Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. British Journal of Haematology, 155, 420-425.
28. Maloney, K., Larsen, E., Mattano, L., Friedmann, A., Devidas, M., Nachman, J., Raetz, E., Winick, N., Whitlock, J., Hunger, S. & Carroll, W. (2011) Improved toxic mortality rates for children with Down syndrome acute lymphoblastic leukemia (DS-ALL) treated on CHIldren's Oncology Group (COG) trials for standrd risk (SR; AALL0331) but not high risk (HR; AALL0232) ALL. Pediatric Blood and Cancer, 56, 900.
29. Mullighan, C.G., Collins-Underwood, J.R., Phillips, L.A., Loudin, M.G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R.C., Willman, C.L., Mikhail, F.M., Meyer, J., Carroll, A.J., Williams, R.T., Cheng, J., Heerema, N.A., Basso, G., Pession, A., Pui, C.H., Raimondi, S.C., Hunger, S.P., Downing, J.R., Carroll, W.L. & Rabin, K.R. (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nature Genetics, 41, 1243-1246.
30. Ritchey, A.K., Pollock, B.H., Lauer, S.J., Andejeski, Y. & Buchanan, G.R. (1999) Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. Journal of Clinical Oncology, 17, 3745-3752.
31. Russell, L.J., Capasso, M., Vater, I., Akasaka, T., Bernard, O.A., Calasanz, M.J., Chandrasekaran, T., Chapiro, E., Gesk, S., Griffiths, M., Guttery, D.S., Haferlach, C., Harder, L., Heidenreich, O., Irving, J., Kearney, L., Nguyen-Khac, F., Machado, L., Minto, L., Majid, A., Moorman, A.V., Morrison, H., Rand, V., Strefford, J.C., Schwab, C., Tonnies, H., Dyer, M.J., Siebert, R. & Harrison, C.J. (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood, 114, 2688-2698.
32. von Stackelberg, A., Hartmann, R., Buhrer, C., Fengler, R., Janka-Schaub, G., Reiter, A., Mann, G., Schmiegelow, K., Ratei, R., Klingebiel, T., Ritter, J., Henze, G. & for the ALL-REZ BFM Study Group. (2008) High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood, 111, 2573-2580.
33. Tallen, G., Ratei, R., Mann, G., Kaspers, G., Niggli, F., Karachunsky, A., Ebell, W., Escherich, G., Schrappe, M., Klingebiel, T., Fengler, R., Henze, G.N. & von Stackelberg, A. (2011) Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. Journal of Clinical Oncology, 28, 2339-2347.
34. Whitlock, J.A. (2006) Down syndrome and acute lymphoblastic leukaemia. British Journal of Haematology, 135, 595-602.